

Lupin Enters into Collaboration to Promote Zymar to Pediatricians in the U.S.

BSE: 500257	NSE: LUPIN	REUTERS: LUPN.BO	BLOOMBERG: LPC IN
-------------	------------	---------------------	----------------------

Mumbai, March 29, 2004: Lupin Limited today announced that its wholly owned subsidiary Lupin Pharmaceuticals, Inc. has entered into an agreement with Allergan, Inc. (NYSE:AGN) in the United States to promote Zymar™ (gatifloxacin ophthalmic solution) 0.3% in the pediatric specialty area.

Zymar™ was approved by the U.S. Food & Drug Administration in March 2003 as the first fourth generation ophthalmic fluoroquinolone to enter the market. Zymar™ is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of bacteria.

Under the terms of the agreement, Lupin Pharmaceuticals' pediatric sales force will promote Zymar™ to high volume pediatric prescribers. Lupin Pharmaceuticals has created a dedicated national pediatric sales force in the US to promote its recently approved product Suprax[®].

Announcing this agreement, the President of Lupin Pharmaceuticals, Inc., Vinita Gupta, said, 'We are pleased to enter into this relationship with Allergan as we launch our presence in the U.S. pediatric specialty segment. We believe that through this relationship, Lupin's sales force will bring to the physician's office two important products for complementary indications. This is a part of our strategy to create a position in the pediatric market segment in the United States. Zymar™ is already the #1 prescribed ophthalmic fluoroquinolone among eye care professionals in the United States.'

Earlier, Lupin had licensed the Suprax[®] trademark on an exclusive basis for the United States to launch Cefixime Dry Suspension and Cefixime Tablet, recently approved by the USFDA. Cefixime is a cephalosporin antibiotic used to treat infections of the ear, throat, urinary tract, respiratory tract (such as bronchitis).

About Lupin

Lupin Pharmaceuticals, Inc is the wholly owned U.S. subsidiary of Mumbai based Lupin Limited, a leading Indian Pharmaceutical company. Lupin Limited develops, manufactures and markets finished products, active pharmaceutical ingredients and

intermediates. Lupin Limited's revenue in FY2002-03 was Rs.11.2 billion. Lupin Limited is traded on all major exchanges in India. Nine of Lupin's plants have been approved by the U.S. Food & Drug Administration and two plants have been approved by the UKMCA.

About Allergan Inc.

Allergan, Inc., with headquarters in Irvine, California, is a technology-driven global healthcare company providing eyecare and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care, neuromodulator and skin care markets that deliver value to customers, satisfy unmet medical needs, and improve patients' lives.

The information presented in this release contains forward looking statements that involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.

[Close](#)